A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

Veitonm?kiN.; HanssonM.; ZhanF.; SundbergA.; L?fstedtT.; LjungarsA.; LiZ.-C.; Martinsson-NiskanenT.; ZengM.; YangY.; DanielssonL.; KovacekM.; LundqvistA.; M?rtenssonL.; TeigeI.; TricotG.; FrendéusB.

首页> 外文期刊>Cancer Cell >A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

【24h】

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

机译：通过功能优先方法分离的人ICAM-1抗体在体内具有有效的巨噬细胞依赖性抗骨髓瘤活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival compared to currently used treatments in advanced experimental models of multiple myeloma.

机译：我们使用具有开拓性的“功能至上”方法，包括筛选（1）对肿瘤B细胞表面受体的特异性，从高度多样化的人噬菌体抗体库中分离出了靶向肿瘤B细胞的抗体BI-505。 2）诱导肿瘤程序性细胞死亡，和（3）与目前使用的治疗方法相比，体内抗肿瘤活性增强。 BI-505与细胞间粘附分子1结合，从而确定了该受体作为癌症治疗靶点的先前未被认识的作用。 BI-505表位在新诊断和复发患者的多发性骨髓瘤细胞表面强烈表达。与目前在多发性骨髓瘤的先进实验模型中使用的治疗方法相比，BI-505具有强效的巨噬细胞依赖性抗骨髓瘤活性，并具有增强的存活率。

著录项

来源
《Cancer Cell》 |2013年第4期|共14页
作者
Veitonm?kiN.; HanssonM.; ZhanF.; SundbergA.; L?fstedtT.; LjungarsA.; LiZ.-C.; Martinsson-NiskanenT.; ZengM.; YangY.; DanielssonL.; KovacekM.; LundqvistA.; M?rtenssonL.; TeigeI.; TricotG.; FrendéusB.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo [J] . Veitonm?kiN., HanssonM., ZhanF., Cancer Cell . 2013,第4期

机译：通过功能优先方法分离的人ICAM-1抗体在体内具有有效的巨噬细胞依赖性抗骨髓瘤活性
2. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer [J] . Ponath Paul, Menezes Daniel, Pan Chin, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第20期

机译：一种新颖的，全人抗FUCOSYL-GM1抗体在小细胞肺癌的临床前模型中体外和体内抗肿瘤活性证明了有效的体外和体内抗肿瘤活性
3. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo [J] . Gaoxin Lei, Menglong Xu, Zhipan Xu, International Journal of Molecular Sciences . 2017,第10期

机译：一种新型的全人类激动性单链片段可变抗体靶向死亡受体5具有有效的体内和体外抗肿瘤活性。
4. KTN0182A, an Anti-KIT, Pyrrolobenzodiazepine (PBD)-Containing Antibody Drug Conjugate (ADC) Demonstrates Potent Antitumor Activity In Vitro and In Vivo Against a Broad Range of Tumor Types [C] . Sergio Trombetta, Christine Lubeski, Gary C. Kemp, PEGS . 2015

机译：KTN0182A，抗试剂盒，吡咯唑二氮杂己酮（PBD）抗体药物缀合物（ADC）在体外和体内抗抗肿瘤类型的抗肿瘤活性
5. A novel approach to control and regulate the classical complement pathway: Highly specific inhibition of C1q globular head binding to human IgG using an engineered single chain antibody variable fragment; recruiting C1q to HER2 /neu positive cells using truncated bispecific antibodies [D] . Hwang, Hee Young 2007

机译：一种控制和调节经典补体途径的新方法：使用工程化的单链抗体可变片段高度特异性地抑制C1q球头与人IgG的结合；使用截短的双特异性抗体将C1q募集到HER2 / neu阳性细胞
6. A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries [O] . Katja Klausz, Michael Cieker, Christian Kellner, 2017

机译：通过噬菌体展示文库的细胞淘选开发出具有强力抗骨髓瘤活性的新型Fc工程化人ICAM-1 / CD54抗体
7. A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo [O] . Veitonmäki Niina, Hansson Markus, Zhan Fenghuang, 2013

机译：通过功能优先方法分离的人ICAM-1抗体在体内具有强大的巨噬细胞依赖性抗骨髓瘤活性

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

摘要

著录项

相似文献

相关主题

期刊订阅